| Literature DB >> 33860383 |
Arjen Mol1,2, Carel G M Meskers3, Marit L Sanders4, Martin Müller5, Andrea B Maier6,7, Richard J A van Wezel8,9, Jurgen A H R Claassen4, Jan Willem J Elting10.
Abstract
PURPOSE: Cerebral autoregulation (CA) aims to attenuate the effects of blood pressure variation on cerebral blood flow. This study assessed the criterion validity of CA derived from near-infrared spectroscopy (NIRS) as an alternative for Transcranial Doppler (TCD).Entities:
Keywords: Cerebral autoregulation; Cognitive dysfunction; Hypertension; Near-infrared spectroscopy; Transcranial Doppler
Mesh:
Year: 2021 PMID: 33860383 PMCID: PMC8260523 DOI: 10.1007/s00421-021-04681-w
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
Cohort characteristics
| Younger controls (cohort 1) | Younger controls (cohort 2) | Older controls | Patients with controlled hypertension | MCI patients | AD patients | |
|---|---|---|---|---|---|---|
| Inclusion | ||||||
| | 39 | 14 | 28 | 27 | 37 | 57 |
| Measurement site | Luzerner Kantonsspitala | UMCGb | Radboudumcc | Lucerne Kantonsspitala | Radboudumcc | Radboudumcc |
| Inclusion/exclusion criteria | No smoking | Age between 20 and 50 years | Age > 50 years | Patients referred for diagnosis of cerebrovascular diseases | Age > 50 years | Age > 50 years |
| Absence of any medical conditions | Absence of any medical conditions | No medical history of cardiovascular or cerebrovascular disease | History of SBP > 140 and/or DBP > 90 for > 2 years, successfully treated | Clinical diagnosis of MCI due to AD according to the NIA-AA criteria | Clinical diagnosis of AD according to the NIA-AA criteria | |
| Not using cardiovascular or psychotropic medication | No more than 50% stenosis of large arteries on duplex US | MOCA score 18–26 | MMSE score between 12 and 26 | |||
| No smoking | ||||||
| No cardiac arrhythmias or heart failure | ||||||
| Data collection | ||||||
| BP device | Finometer Prod | Portapresd | Finometer Prod | Finometer Prod | Finometer Prod | Finometer Prod |
| TCD device (sampling frequency) | Multidope (2 MHz) | Delicaf (2 MHz) | Multidope (2 MHz) | Multidope (2 MHz) | Doppler-BoxXe (2 MHz) | Multidope (2 MHz) |
| NIRS device (sampling frequency) | NIRO-200NXg (5 Hz) | Portaliteh (50 Hz) | Oxymon Mk IIIg (10 Hz) | NIRO-200NXg (5 Hz) | Oxymon Mk IIIh (10 Hz) | Oxymon Mk IIIh (10 Hz) |
| NIRS wavelengths | 735, 810 and 850 nm | 760 and 850 nm | 765, 857 and 859 nm | 735, 810 and 850 nm | 765, 857 and 859 nm | 765, 857 and 859 nm |
| NIRS inter optode distance | 4 cm | 4.0 cm | 5 cm | 4 cm | 5 cm | 5 cm |
MCI mild cognitive impairment, AD Alzheimer’s dementia, BP blood pressure, TCD Transcranial Doppler, NIRS near-infrared spectroscopy, SBP systolic blood pressure, DBP diastolic blood pressure, US ultrasound, MOCA Montreal Cognitive Assessment, MMSE Mini-Mental State Examination
aDepartment of Neurology, Lucerne Kantonsspital, Lucerne, Switzerland
bUniversity Medical Center Groningen, Groningen, the Netherlands
cRadboud University Medical Center, Nijmegen, the Netherlands
dFinapres Medical Systems, Amsterdam, The Netherlands
eCompumedics DWL, Singen, Germany
fShenzhen, China
gHasamotu Photonics, Herrsching, Germany
hArtinis Medical Systems, Elst, The Netherlands
Fig. 1Grand average of BP-CBFV and BP-O2Hb TFφ in supine rest and during repeated sit to stand transitions, per cohort. The blue and red traces are the BP-O2Hb TFφs before and after correction, respectively. The yellow dotted lines are the means lines of the BP-O2Hb TFφ in the high frequency (HF) range. MCI mild cognitive impairment, AD Alzheimer’s dementia
Characteristics of patients and controls
| Characteristic | Younger controls (cohort 1; | Younger controls (cohort 2; | Older controls ( | Patients with controlled hypertension ( | MCI patients ( | AD patients ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, years, mean (SD/range) | 39 | 48.0 (17.7) | 14 | 28 (21–45) | 28 | 70.0 (3.7) | 27 | 67.0 (14.7) | 37 | 69.2 (8.4) | 57 | 73.3 (6.1) |
| Female, | 39 | 17 (43.6) | 14 | 11 (78.6) | 28 | 12 (42.9) | 27 | 5 (18.5) | 37 | 12 (32.4) | 57 | 32 (56.1) |
| BMI, kg/m2, mean (SD) | 39 | < 30 | NA | 28 | 26.2 (2.9) | 27 | < 30 | 37 | 26.0 (3.7) | 57 | 24.8 (3.7) | |
| Current smoking, | 39 | 0 (0) | NA | NA | 27 | 0 (0) | 31 | 4 (12.9) | NA | |||
| Cardiovascular or cerebrovascular disease, | 39 | 0 (0) | 14 | 0 (0) | 28 | 0 (0) | 27 | 27 (100) | 30 | 9 (30.0) | 57 | 43 (75.4) |
| Cardiovascular or psychotropic medication, | 39 | 0 (0) | 14 | 0 (0) | 28 | 0 (0) | 27 | 27 (100) | 19 | 13 (68.4) | 57 | 16 (28.1) |
| MMSE, points, median [IQR] | NA | NA | 28 | 29 [28–30] | NA | NA | 57 | 16 [14–18] | ||||
| MOCA, points, median [IQR] | NA | NA | NA | NA | 37 | 23 [20.5–25] | NA | |||||
| Blood pressure and cerebral blood flow velocity | ||||||||||||
| SBP, mmHg, mean (SD) | 39 | 113.8 (16.6)a | 14 | 129.8 (21.8)a | 28 | 132.9 (12.8)b | 26 | 124.0 (15.6)a | 37 | 142.8 (22.0)b | 57 | 138 (13.1)b |
| DBP, mmHg, mean (SD) | 39 | 68.4 (12.1)a | 14 | 79.4 (18.2)a | 28 | 78.5 (9.6)b | 26 | 67.5 (12.9)a | 37 | 83.8 (12.2)b | 57 | 78.4 (6.4)b |
| Cerebral blood flow velocity, cm/s, mean (SD) | 39 | 62.8 (13.6) | 14 | 62.3 (8.7) | 23 | 46.0 (8.8) | 26 | 53.2 (12.8) | 33 | 41.8 (12.3) | 39 | 38.2 (9.6) |
The table lists patient characteristics for each of the included cohorts. SD standard deviation, IQR interquartile range, BMI Body Mass Index, MMSE mini-mental state examination, MOCA Montreal cognitive assessment, HR heart rate, bpm beats per minute, SBP systolic blood pressure, DBP diastolic blood pressure, CBFV cerebral blood flow velocity, VLF very low-frequency range, LF low-frequency range, HF high-frequency range, MCI mild cognitive impairment, AD Alzheimer’s dementia, BP blood pressure
aMeasured using continuous BP monitor
bMeasured using a sphygmomanometer
Cerebral autoregulation estimates derived from TCD and NIRS
| Supine rest | Sit to stand transitions | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Younger controls ( | Older controls ( | Patients with controlled hypertension ( | Cognitively impaired patients ( | All ( | Cognitively impaired patients ( | |||||||
| BP-CBFV and BP-O2Hb | ||||||||||||
| VLF | ||||||||||||
| GA error bc, mean (SD), degreesa | 39b | − 40 (20) | 17b | − 42 (13) | 18b | − 41 (12) | 46b | − 46 (17) | 120b | − 43 (16) | 32b | − 62 (5) |
| GA error ac, mean (SD), degreesa | 39b | 23 (20) | 17b | 18 (12) | 18b | 14 (11) | 46b | 12 (17) | 120b | 16 (16) | 32b | − 4 (5) |
| Spearman correlation | 39 | 0.00 | 17 | 0.24 | 18 | 0.55* | 46 | 0.24 | 120 | 0.22* | 32 | 0.46** |
| BA bias (loa), degrees | 39 | 24 (149) | 17 | 16 (65) | 18 | 13 (82) | 46 | 7 (91) | 120 | 14 (112) | 32 | − 0 (78) |
| LF | ||||||||||||
| GA error bc, mean (SD), degreesa | 36b | − 65 (7) | 15b | − 72 (7) | 17b | − 69 (8) | 46b | − 76 (13) | 111b | − 71 (4) | 19b | − 75 (7) |
| GA error ac, mean (SD), degreesa | 36b | − 2 (7) | 15b | − 12 (6) | 17b | − 12 (7) | 46b | − 19 (13) | 111b | − 12 (3) | 19b | − 17 (7) |
| Spearman correlation | 36 | 0.37* | 15 | 0.16 | 17 | − 0.06 | 43 | 0.30 | 111 | 0.30** | 19 | 0.62** |
| BA bias (loa), degrees | 36 | 2 (109) | 15 | − 10 (52) | 17 | − 2 (73) | 43 | − 11 (71) | 111 | − 5 (86) | 19 | − 4 (65) |
Grand average (GA) errors before and after correction (bc and ac, respectively), and Spearman correlations and Bland Altman (BA) analysis results between NIRS- and TCD-derived CA measures within pooled cohorts. BP blood pressure, CBFV cerebral blood flow velocity, OHb oxygenated hemoglobin. loa separation between 95% upper and lower limits of agreement. One and two stars indicate statistically significant correlations with p values lower than 0.05 and 0.01, respectively
aMean and standard deviation over frequencies within the frequency range
bRepresents the number of patients for whom both BP-CBFV and BP-O2Hb TFs was available. The number of patients for whom the separate TFs were available (enabling them to be included in the TF grand average) was higher (see Supplementary Table S2) ed cohort SD standard deviation
Fig. 2Bland Altman plots showing agreement between NIRS- and TCD- derived CA measures during supine rest and repeated sit-to-stand transitions. The horizontal solid lines indicate the mean difference; the horizontal dashed lines indicate the 95% limits of agreement. VLF very low-frequency range, LF low-frequency range